Literature DB >> 28222305

Consumer use and understanding of labelling information on edible marijuana products sold for recreational use in the states of Colorado and Washington.

Katherine M Kosa1, Kristen C Giombi1, Caroline B Rains1, Sheryl C Cates2.   

Abstract

BACKGROUND: In 2014, the states of Colorado and Washington began allowing retail sales of marijuana for recreational use. The regulatory agencies in these states have implemented specific labelling requirements for edible marijuana products sold for recreational use to help address concerns such as delayed activation time, accidental ingestion, and proper dosing.
METHODS: We conducted 12 focus groups with 94 adult consumers and nonconsumers of edibles in Denver and Seattle to collect information on their use and understanding of labelling information on edible marijuana products sold for recreational use. Specifically, we asked participants about the usefulness, attractiveness, ease of comprehension, relevancy, and acceptability of the label information.
RESULTS: Some focus group participants look for and read specific information, such as the potency profile and serving size statement, but do not read or were unfamiliar with other labelling features. The focus groups revealed that participants have some concerns about the current labelling of edibles. In particular, participants were concerned that there is too much information on the labels so consumers may not read the label, there is no obvious indication that the product contains marijuana (e.g., a Universal Symbol), and the information on consumption advice is not clear. Participants in both locations suggested that education in a variety of formats, such as web- and video-based education, would be useful in informing consumers about the possible risks of edibles.
CONCLUSION: The focus group findings suggest that improvements are needed in the labelling of edibles to prevent unintentional ingestion among adult nonusers and help ensure proper dosing and safe consumption among adult users. These findings, along with lessons learned from Colorado and Washington, can help inform the labelling of edibles as additional states allow the sale of edibles for recreational use.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cannabis; Edibles; Labelling; Marijuana; Recreational use

Mesh:

Year:  2017        PMID: 28222305     DOI: 10.1016/j.drugpo.2017.01.006

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  7 in total

Review 1.  Interpol review of controlled substances 2016-2019.

Authors:  Nicole S Jones; Jeffrey H Comparin
Journal:  Forensic Sci Int Synerg       Date:  2020-05-24

2.  Cannabis use frequency, route of administration, and co-use with alcohol among older adults in Washington state.

Authors:  Meenakshi S Subbaraman; William C Kerr
Journal:  J Cannabis Res       Date:  2021-06-03

3.  Associations of mode of administration on cannabis consumption and subjective intoxication in daily life.

Authors:  Renee M Cloutier; Brian H Calhoun; Ashley N Linden-Carmichael
Journal:  Psychol Addict Behav       Date:  2021-09-02

4.  Associations between self-reported cannabis use frequency, potency, and cannabis/health metrics.

Authors:  Christine M Steeger; Leah N Hitchcock; Angela D Bryan; Kent E Hutchison; Karl G Hill; L Cinnamon Bidwell
Journal:  Int J Drug Policy       Date:  2021-05-30

5.  Knowledge of Tetrahydrocannabinol and Cannabidiol Levels Among Cannabis Consumers in the United States and Canada.

Authors:  David Hammond; Samantha Goodman
Journal:  Cannabis Cannabinoid Res       Date:  2020-10-29

Review 6.  The importance of psychology for shaping legal cannabis regulation.

Authors:  Jacob T Borodovsky; Michael J Sofis; Richard A Grucza; Alan J Budney
Journal:  Exp Clin Psychopharmacol       Date:  2020-05-21       Impact factor: 3.157

Review 7.  Cannabis Legalization and Acute Harm From High Potency Cannabis Products: A Narrative Review and Recommendations for Public Health.

Authors:  Justin Matheson; Bernard Le Foll
Journal:  Front Psychiatry       Date:  2020-09-23       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.